Global Herpes Simplex Virus (HSV) Vaccines Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Herpes Simplex Virus (HSV) Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Herpes Simplex Virus (HSV) Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Herpes Simplex Virus (HSV) Vaccines market include Sanofi, GlaxoSmithKline, Vical and Genocea Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Herpes Simplex Virus (HSV) Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Herpes Simplex Virus (HSV) Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Herpes Simplex Virus (HSV) Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Herpes Simplex Virus (HSV) Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Herpes Simplex Virus (HSV) Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Herpes Simplex Virus (HSV) Vaccines sales, projected growth trends, production technology, application and end-user industry.
Herpes Simplex Virus (HSV) Vaccines Segment by Company
Sanofi
GlaxoSmithKline
Vical
Genocea Biosciences
Herpes Simplex Virus (HSV) Vaccines Segment by Type
VCL-HB01
HSV529
GEN-003
Others
Herpes Simplex Virus (HSV) Vaccines Segment by Application
HSV-1 (Oral Herpes)
HSV-2 (Genital Herpes)
Herpes Simplex Virus (HSV) Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Herpes Simplex Virus (HSV) Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Herpes Simplex Virus (HSV) Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Herpes Simplex Virus (HSV) Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Herpes Simplex Virus (HSV) Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Simplex Virus (HSV) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herpes Simplex Virus (HSV) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Simplex Virus (HSV) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Herpes Simplex Virus (HSV) Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Herpes Simplex Virus (HSV) Vaccines industry.
Chapter 3: Detailed analysis of Herpes Simplex Virus (HSV) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Herpes Simplex Virus (HSV) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Herpes Simplex Virus (HSV) Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Herpes Simplex Virus (HSV) Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Herpes Simplex Virus (HSV) Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Herpes Simplex Virus (HSV) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Herpes Simplex Virus (HSV) Vaccines market include Sanofi, GlaxoSmithKline, Vical and Genocea Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Herpes Simplex Virus (HSV) Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Herpes Simplex Virus (HSV) Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Herpes Simplex Virus (HSV) Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Herpes Simplex Virus (HSV) Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Herpes Simplex Virus (HSV) Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Herpes Simplex Virus (HSV) Vaccines sales, projected growth trends, production technology, application and end-user industry.
Herpes Simplex Virus (HSV) Vaccines Segment by Company
Sanofi
GlaxoSmithKline
Vical
Genocea Biosciences
Herpes Simplex Virus (HSV) Vaccines Segment by Type
VCL-HB01
HSV529
GEN-003
Others
Herpes Simplex Virus (HSV) Vaccines Segment by Application
HSV-1 (Oral Herpes)
HSV-2 (Genital Herpes)
Herpes Simplex Virus (HSV) Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Herpes Simplex Virus (HSV) Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Herpes Simplex Virus (HSV) Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Herpes Simplex Virus (HSV) Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Herpes Simplex Virus (HSV) Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Simplex Virus (HSV) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herpes Simplex Virus (HSV) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Simplex Virus (HSV) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Herpes Simplex Virus (HSV) Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Herpes Simplex Virus (HSV) Vaccines industry.
Chapter 3: Detailed analysis of Herpes Simplex Virus (HSV) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Herpes Simplex Virus (HSV) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Herpes Simplex Virus (HSV) Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
196 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 1.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume (2020-2031)
- 1.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Herpes Simplex Virus (HSV) Vaccines Market Dynamics
- 2.1 Herpes Simplex Virus (HSV) Vaccines Industry Trends
- 2.2 Herpes Simplex Virus (HSV) Vaccines Industry Drivers
- 2.3 Herpes Simplex Virus (HSV) Vaccines Industry Opportunities and Challenges
- 2.4 Herpes Simplex Virus (HSV) Vaccines Industry Restraints
- 3 Herpes Simplex Virus (HSV) Vaccines Market by Company
- 3.1 Global Herpes Simplex Virus (HSV) Vaccines Company Revenue Ranking in 2024
- 3.2 Global Herpes Simplex Virus (HSV) Vaccines Revenue by Company (2020-2025)
- 3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Company (2020-2025)
- 3.4 Global Herpes Simplex Virus (HSV) Vaccines Average Price by Company (2020-2025)
- 3.5 Global Herpes Simplex Virus (HSV) Vaccines Company Ranking (2023-2025)
- 3.6 Global Herpes Simplex Virus (HSV) Vaccines Company Manufacturing Base and Headquarters
- 3.7 Global Herpes Simplex Virus (HSV) Vaccines Company Product Type and Application
- 3.8 Global Herpes Simplex Virus (HSV) Vaccines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Herpes Simplex Virus (HSV) Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Herpes Simplex Virus (HSV) Vaccines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Herpes Simplex Virus (HSV) Vaccines Market by Type
- 4.1 Herpes Simplex Virus (HSV) Vaccines Type Introduction
- 4.1.1 VCL-HB01
- 4.1.2 HSV529
- 4.1.3 GEN-003
- 4.1.4 Others
- 4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type
- 4.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2020-2031)
- 4.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Type (2020-2031)
- 4.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type
- 4.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2020-2031)
- 4.3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type (2020-2031)
- 5 Herpes Simplex Virus (HSV) Vaccines Market by Application
- 5.1 Herpes Simplex Virus (HSV) Vaccines Application Introduction
- 5.1.1 HSV-1 (Oral Herpes)
- 5.1.2 HSV-2 (Genital Herpes)
- 5.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application
- 5.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2020-2031)
- 5.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Application (2020-2031)
- 5.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application
- 5.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2020-2031)
- 5.3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application (2020-2031)
- 6 Herpes Simplex Virus (HSV) Vaccines Regional Sales and Value Analysis
- 6.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2020-2031)
- 6.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2020-2025
- 6.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2026-2031)
- 6.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2020-2031)
- 6.4.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region: 2020-2025
- 6.4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2026-2031)
- 6.5 Global Herpes Simplex Virus (HSV) Vaccines Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 6.6.2 North America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 6.7.2 Europe Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 6.9.2 South America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2024 VS 2031
- 7 Herpes Simplex Virus (HSV) Vaccines Country-level Sales and Value Analysis
- 7.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2020-2031)
- 7.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2020-2025)
- 7.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2026-2031)
- 7.4 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2020-2031)
- 7.4.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2020-2025)
- 7.4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.9.2 France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.16.2 China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.19.2 India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Comapny Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Sanofi Herpes Simplex Virus (HSV) Vaccines Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 GlaxoSmithKline
- 8.2.1 GlaxoSmithKline Comapny Information
- 8.2.2 GlaxoSmithKline Business Overview
- 8.2.3 GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.2.4 GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Product Portfolio
- 8.2.5 GlaxoSmithKline Recent Developments
- 8.3 Vical
- 8.3.1 Vical Comapny Information
- 8.3.2 Vical Business Overview
- 8.3.3 Vical Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Vical Herpes Simplex Virus (HSV) Vaccines Product Portfolio
- 8.3.5 Vical Recent Developments
- 8.4 Genocea Biosciences
- 8.4.1 Genocea Biosciences Comapny Information
- 8.4.2 Genocea Biosciences Business Overview
- 8.4.3 Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Product Portfolio
- 8.4.5 Genocea Biosciences Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Herpes Simplex Virus (HSV) Vaccines Value Chain Analysis
- 9.1.1 Herpes Simplex Virus (HSV) Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Herpes Simplex Virus (HSV) Vaccines Sales Mode & Process
- 9.2 Herpes Simplex Virus (HSV) Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Herpes Simplex Virus (HSV) Vaccines Distributors
- 9.2.3 Herpes Simplex Virus (HSV) Vaccines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


